🔬 New at Pharmidex: In Vivo CAR-T Studies
February 12, 2026

Pharmidex now offers integrated in vivo CAR-T study support, combining robust in-life pharmacology with advanced flow cytometry–based cellular analysis.

We support early-stage CAR-T and cell therapy programmes with translational data on efficacy, expansion, persistence and phenotype delivered through a single collaborative CRO partner.


Let’s talk.

 🌐 www.pharmidex.com

#Pharmidex #CART #CellTherapy #PreclinicalResearch #ImmunoOncology


February 11, 2026
Pharmidex is pleased to share that Janette Dalay Robertson will be attending the Founders Growth Community Meeting and Networking x Innovate Cambridge event at The Glasshouse, Cambridge. Janette will be available to meet between 12:00–15:30 and looks forward to connecting with fellow attendees to explore new alliances in pre-clinical and clinical drug development. If you’re attending, let’s connect.
February 9, 2026
We’re excited to announce that Pharmidex has expanded its analytical capabilities with the addition of the xMAP INTELLIFLEX™ system, a powerful, high-performance platform for multiplex biomarker analysis. This advanced technology enables the simultaneous measurement of multiple analytes from minimal sample volumes, delivering exceptional sensitivity, accuracy and reproducibility. It is ideally suited for complex biological matrices and supports a wide range of applications, from biomarker discovery to translational and preclinical studies.  Our INTELLIFLEX™ supports dual reporter channels to collect more data per sample. 🔬 What this means for our partners and the wider scientific community: • Faster, data-rich insights from fewer samples • Enhanced assay flexibility and scalability • Improved data quality to support confident decision-making • Greater efficiency across drug discovery and development programmes This investment strengthens Pharmidex’s commitment to scientific excellence, allowing us to deliver even more robust, innovative and reliable services to pharma, biotech, CROs and academic collaborators. We look forward to putting this new capability to work in support of better science and better medicines.
February 4, 2026
At Pharmidex , we deliver high-quality LC-MS bioanalysis to support drug development across a wide range of analysis. Our experienced team supports preclinical, translational and clinical studies, providing accurate, reliable data under GLP and GCP to help drive confident decision-making. Learn more about our LC-MS capabilities: https://www.pharmidex.com/Discovery-Bioanalysis
More Posts